Autism is a complex interplay of symptoms that extend far beyond the diagnostic labels commonly associated with mental health conditions. From mood dysregulation and attentional challenges to trauma ...
By targeting complex conditions such as treatment-resistant depression, social anxiety disorder and opioid use disorder, Atai aims to address significant gaps in the mental health treatment landscape.
The company is set to begin Phase 2 trials for VLS-01 in treatment-resistant depression and EMP-01 for social anxiety disorder by the end of 2024. With FDA clearance for VLS-01 and a strategic ...